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TLR7 agonists are being progressed as potential immu-
notherapeutics for the treatment of cancer. TLR7 agon-
ism is believed to trigger a plasmacytoid dendritic cell
driven immune response which drives anti-tumor effi-
cacy. In addition to modulation of the immune system,
TLR7 may be involved in tumor progression due to
expression of TLR7 by tumor cells themselves [1]. To
determine the precise distribution of TLR7 in different
tumor types, a comprehensive validation of anti-TLR7
antibodies was conducted by immuohistochemistry
(IHC). One antibody (Epitomics, 3923-1), out of five
selected from scientific citations, proved specific for
TLR7 following analyses by western blot of cell lysates,
and by IHC of formalin fixed paraffin embedded (FFPE)
cell pellets, prepared from HEK293 cells either stably
transfected, mock-transfected or non-transfected with
TLR7. 3923-1 was validated further across human
spleen, lymph node and tonsil, revealing the expected
tissue and cellular localization for these lymphoid
organs. Assessment of TLR7 expression in a selection of
tumor samples revealed non-specific tumor cell staining
for the rejected antibodies, compared with minimal
tumor staining for 3923-1. To explore further the distri-
bution of TLR7, 5 tissue microarrays comprising 18 differ-
ent human tumor types (6-25 patients/tumor type, triplicate
cores) and 14 normal tissues (5 donors/tissue type, dupli-
cate cores) were examined by IHC using 3923-1. Staining
for TLR7 was scored by a pathologist (4-point scale: 0 nega-
tive, 1+ weak, 2+ moderate, 3+ strong) for tumor and
immune cell compartments. Out of 18 tumor types exam-
ined, 5 were negative for tumor cell expression of TLR7
(ovarian, glioma, thyroid, liver, renal) and 9 exhibited a pro-
portion (4%-36%) of patients with weak staining (breast,
lung, colorectal, pancreatic, gastric, head & neck, mela-
noma, esophageal, endometrial). Moderate staining was
observed for 11%-17% of sarcoma, prostate and bladder
tumors. Corresponding normal tissue epithelium was lar-
gely negative for TLR7. Importantly, an increased density of
immune infiltrates was observed in tumor tissues compared
with normal tissues, and a greater proportion of the
immune infiltrates were TLR7 positive. These data demon-
strate that TLR7 may be less frequently expressed by tumor
cells than suggested by the literature and that all tumor
types exhibit a marked TLR7 positive immune cell infiltrate.
Together, these data identify tumour types that might bene-
fit from TLR7 therapy and may guide patient selection.
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